BioVersys AG (CHIX:BIOVZ) Beneish M-Score


CHIX:BIOVZ BioVersys AG CHIX:BIOVZ
14 GF Score
Price CHF27.10
View Full Analysis

What is BioVersys AG Beneish M-Score?

BioVersys AG does not have enough data to calculate Beneish M-Score.

BioVersys AG Beneish M-Score Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Beneish M-Score Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Beneish M-Score
0.00 0.00

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Beneish M-Score 0.00 0.00 0.00 0.00

CHIX:BIOVZ vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, BioVersys AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVersys AG Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioVersys AG's Beneish M-Score falls into.


CHIX:BIOVZ
14GF Score
BioVersys AG CHIX:BIOVZ
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Business Description

Other Exchanges W33:GermanyBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
14GF Score

Get the complete analysis for CHIX:BIOVZ

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.10
Price